The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 09, 2016
Filed:
Mar. 02, 2011
Ju-hee Ryu, Seoul, KR;
Kwang-meyung Kim, Seoul, KR;
Ick-chan Kwon, Seoul, KR;
Kui-won Choi, Seoul, KR;
Sang-yoon Kim, Seoul, KR;
Beom-suk Lee, Seoul, KR;
Dae-yoon Chi, Seoul, KR;
Hee-seup Kil, Seoul, KR;
Hyun-ju Sung, Seoul, KR;
Ju-Hee Ryu, Seoul, KR;
Kwang-Meyung Kim, Seoul, KR;
Ick-Chan Kwon, Seoul, KR;
Kui-Won Choi, Seoul, KR;
Sang-Yoon Kim, Seoul, KR;
Beom-Suk Lee, Seoul, KR;
Dae-Yoon Chi, Seoul, KR;
Hee-Seup Kil, Seoul, KR;
Hyun-Ju Sung, Seoul, KR;
KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, Seoul, KR;
Abstract
The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.